The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Open accessAbstract
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits immune cell activity while anti-VEGF augments intra-tumoral T-cell infiltration, potentially through vascular normalization and endothelial cell activation. This study investigates how VEGF blockade with bevacizumab could potentiate PD-L1 checkpoint inhibition with atezolizumab in mRCC. Tissue collections are before treatment, after bevacizumab and after the addition of atezolizumab. We discover that intra-tumoral CD8+ T cells increase following combination treatment. A related increase is found in intra-tumoral MHC-I, Th1 and T-effector markers, and chemokines, most notably CX3CL1 (fractalkine). We also discover that the fractalkine receptor increases on peripheral CD8+ T cells with treatment. Furthermore, trafficking lymphocyte increases are observed in tumors following bevacizumab and combination treatment. These data suggest that the anti-VEGF and anti-PD-L1 combination improves antigen-specific T-cell migration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Latchman, Y. E., Liang, S. C., Wu, Y., Chernova, T., Sobel, R. A., Klemm, M., Kuchroo, V. K., Freeman, G. J., & Sharpe, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307252101 · Cited by 636
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Self-citationUsing synthetic templates to design an unbiased multiplex PCR assay
Carlson, C. S., Emerson, R. O., Sherwood, A. M., Desmarais, C., Chung, M.-W., Parsons, J. M., Steen, M. S., LaMadrid-Herrmannsfeldt, M. A., Williamson, D. W., Livingston, R. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3680 · Cited by 565
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Self-citationNishimura, M., Umehara, H., Nakayama, T., Yoneda, O., Hieshima, K., Kakizaki, M., Dohmae, N., Yoshie, O., & Imai, T. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6173 · Cited by 326
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
Fractalkine in Vascular Biology: From Basic Research to Clinical Disease
Umehara, H., Bloom, E. T., Okazaki, T., Nagano, Y., Yoshie, O., & Imai, T. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000095360.62479.1f · Cited by 319
Dual role of macrophages in tumor growth and angiogenesis
Lamagna, C., Aurrand-Lions, M., & Imhof, B. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105656 · Cited by 311
Kessler, J. H., Beekman, N. J., Bres-Vloemans, S. A., Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M., Vissers, D. C. J., ten Bosch, G. J. A., Kester, M. G. D., Sijts, A., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.1.73 · Cited by 263
Angiogenic inhibitors: a new therapeutic strategy in oncology
Gasparini, G., Longo, R., Toi, M., & Ferrara, N. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0342 · Cited by 212
Manning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Akbari, O., Stock, P., Singh, A. K., Lombardi, V, Lee, W.-L., Freeman, G. J., Sharpe, A. H., Umetsu, D. T., & DeKruyff, R. H. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.112 · Cited by 182
Klinger, M., Pepin, F., Wilkins, J., Asbury, T., Wittkop, T., Zheng, J., Moorhead, M., & Faham, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141561 · Cited by 141
Brauer, M. J., Zhuang, G., Schmidt, M., Yao, J. J., Wu, X., Kaminker, J. S., Jurinka, S. S., Kolumam, G. A., Chung, A. S., Jubb, A. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3635 · Cited by 64
Self-citationB7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma
Matsumoto, K., Fukuyama, S., Tsuda, M., Nakano, T., Matsumoto, T., Matsumura, M., Moriwaki, A., Kan‐o, K., Wada, Y., Yagita∥, H., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.156 · Cited by 51
Szukiewicz, D., Kochanowski, J., Pyźlak, M., Szewczyk, G., Stangret, A., & Mittal, T. K. (2013) · Mediators of Inflammation · doi:10.1155/2013/437576 · Cited by 47
Ghosh, S., Paul, A., & Sen, E. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01254-12 · Cited by 46
Flörcken, A., Kopp, J., van Lessen, A., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24149 · Cited by 34
Cited by
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Self-citation
Metadata
- Authors
- Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., Denker, M., Leveque, V., Cañamero, M., Babitski, G., Koeppen, H., Ziai, J., Sharma, N., Gaire, F., Chen, D. S., Waterkamp, D., Hegde, P. S., & McDermott, D. F.
- Venue
- Nature Communications
- Published
- 2016-08-30
- Volume
- 7
- Issue
- 1
- Pages
- 12624-12624
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2511951051
- Cited by
- 713
- References
- 27
- FWCI
- 29.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.